Format

Send to

Choose Destination
See comment in PubMed Commons below
J Health Care Poor Underserved. 2011 Feb;22(1):24-49. doi: 10.1353/hpu.2011.0003.

What is the evidence for pharmaceutical patient assistance programs? A systematic review.

Author information

1
Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy & Statewide Cancer Prevention Control Program, University of South Carolina, Columbia, SC 29208, USA. feldert@sccp.sc.edu

Abstract

Pharmaceutical patient assistance programs (PAPs) have the potential to improve prescription drug accessibility for eligible patients, but currently there is limited information regarding their effectiveness. In an attempt to provide a systematic description of primary studies on PAPs, we reviewed 33 unique studies from commercial and grey literature (e.g., government publications, conference abstracts) sources: 15 health care outcome evaluations, seven economic evaluations, seven surveys and four miscellaneous studies. Enrollment assistance for PAPs with additional medication services (e.g., counseling) was significantly associated with improved glycemic (standardized mean difference=-0.40, 95% CI=-0.59,-0.20; k=3 one-group, pre-post-test; 1 comparison-group) and lipid (standardized mean difference=-0.52, 95% CI=0.78,-0.27; k=3 one-group, pre-post-test; 1 comparison group) control. Inadequately designed economic evaluations suggest free PAP medications offset health care institutions' costs for uncompensated medications and enrollment assistance programs. More rigorous research is needed to establish the clinical and cost-effectiveness of PAPs from a patient and health care institution perspective.

PMID:
21317504
PMCID:
PMC3065996
DOI:
10.1353/hpu.2011.0003
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Project MUSE Icon for PubMed Central
    Loading ...
    Support Center